Loading…

AmgenAMGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Large biotechnology company developing biologic drugs for inflammation, bone disease, oncology and cardiovascular conditions, with an obesity pipeline.

Momentum leader 82
Mkt cap
$240B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$1.22B
20-day average traded
Fwd P/E
18.3×
forward earnings
ROIC−WACC
+13.0 pp
WACC 6.9%
Hurdle
-6 pp
Req g minus delivered
Official | Implied
BBB+ / A-
agencies · bond market
Next earnings
83 days
9 Feb 2027
Close · USD$443.89
1D-3.1%
1W-5.2%
1M+1.1%
3M+2.3%
6M+33.9%
YTD+37.6%
1Y+32.7%
ATR %2.7%
Beta0.51
52w lowhigh8.3% off high

What Amgen does

Large biotechnology company developing biologic drugs for inflammation, bone disease, oncology and cardiovascular conditions, with an obesity pipeline.

Sells patented biologic drugs through hospitals, specialty pharmacies and payers, and also sells biosimilars, copies of other companies' biologics. Buying Horizon Therapeutics in 2023 added rare-disease and inflammation drugs, and several of its older products face biosimilar competition.

Products and services

  • Repatha (cholesterol)
  • Prolia/EVENITY (bone)
  • Enbrel (inflammation)
  • MariTide (obesity, pipeline)

Customers

  • Physicians/hospitals treating chronic and oncology
  • Payers/PBMs

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Biologic drug discovery, development…

What could go right

  • Obesity drug pipeline potential (MariTide)
  • Growth of newer biologics (Tezspire, EVENITY)

What could go wrong

  • Patent expirations/biosimilar competition (Enbrel, others)
  • US drug pricing policy risk

Moat: wide (IP / patents, scale, regulatory licence). Deep biologics manufacturing know-how and patent-protected franchises support high margins despite biosimilar threats.

Headquarters: Thousand Oaks, California, US · Founded: 1980 · Employees: 31,500

Named competitors

Amgen at a glance

Size Amgen (AMGN) is a United States Health Care company (Biotechnology) with a market value of $240B, the 49th largest of 3,085 United States companies the cockpit tracks. Shares closed at $443.89 on 18 Nov 2026.

Performance Over six months the shares gained 33.9%, against +29.1% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 8.6% over the last twelve months (peer median +13.9%); the operating margin is 35.6% (peer median 25.1%).

Valuation It trades at 18.3× forward earnings against a peer median of 22.7× (5th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.0 points above its cost of capital (6.9% WACC).

Credit Amgen has 42 bonds outstanding ($55.8B), rated BBB+ by the agencies and trading like A- at a weighted spread of 82 bp.

Short interest Short interest is 2.3% of the free float (30 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026AMGN 132Peer median 128
Six months, rebased to 100: Amgen against the median of its 20 peers (local-currency closes).

Amgen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$39.0B$36.7B$33.2B$28.0B$26.1B
Revenue growth—+11%+19%+7%—
Gross profit$28.8B$26.0B$21.3B$20.3B$19.7B
EBITDA$18.4B$15.8B$13.9B$13.1B$12.6B
Net income$9.39B$7.71B$4.09B$6.72B$6.55B
Free cash flow$9.58B$8.10B$10.4B$7.36B$8.79B
Capital expenditure$2.45B$1.86B$1.10B$1.11B$936M
Total debt$54.0B$55.4B$60.9B$65.4B$39.6B

Quarterly statements and history in the cockpit →

Amgen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%GILDMRNACSLARGXLONN207940IQVNTRA068270GMABUTHR2269BNTXNBIXBBIOELAN1093TECHHALOAMGN6-month return →1-month return →
Up and to the right = strong over both horizons. Amgen is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%10×20×30×40×GILDCSLARGXLONN207940IQV068270GMABUTHR2269NBIXELAN1093BMRNTECHHALOAMGNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Amgen is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%GILDCSLARGXLONN207940GMABUTHR2269ELAN1093HALOAMGNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Amgen is the large dot.

Amgen competitors and peer comparison

Head to head with its named competitors (AMGN vs LLY vs NOVN.SW vs REGN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Amgen AMGN$240B+34%+9%36%18.3×1.6%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%11.8×-1.1%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%

How Amgen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Amgen against its 20 peers (data as of 18 Nov 2026)
MeasureAMGNPeer medianRank in peer set
1-month return+1.1%+2.9%10th lowest of 21
6-month return+33.9%+29.1%10th highest of 21
Distance from 52-week high-8.3%-12.8%7th highest of 21
Revenue growth (TTM)+8.6%+13.9%8th lowest of 21
Operating margin35.6%25.1%5th highest of 21
Forward P/E18.3×22.7×5th cheapest of 17
Growth the price implies (Req g, 7 yrs)1.6%9.4%6th least demanding of 17
Growth delivered (Del g)+7.8%+14.2%7th lowest of 17
Hurdle (Req g minus delivered)-6.2 pp-7.5 pp8th most demanding of 17
ROIC minus cost of capital+13.0 pp+2.2 pp8th highest of 21
EV / EBITDA15.3×16.0×5th cheapest of 17
Net debt / EBITDA2.2×1.2×5th most indebted of 17
Bond spread82 bp98 bp3rd tightest of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Amgen AMGNUnited States$240B+34%+9%36%18.3×1.6%+7.8%
Gilead Sciences GILDUnited States$210B+30%+7%38%19.9×-2.4%+3.6%
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%

Amgen bonds and credit

Amgen has 42 bonds outstanding with $55.8B face value. The agencies rate it BBB+; its bonds trade like A-. Weighted yield 5.77%, a spread of 82 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Amgen's main competitors?
Named competitors: Eli Lilly (LLY), Novartis (NOVN.SW), Regeneron Pharmaceuticals (REGN), AbbVie (ABBV). The cockpit's measured peer set (industry) also includes Gilead Sciences (GILD), Moderna (MRNA), CSL (CSL.AX), argenx SE Sponsored ADR (ARGX), Lonza (LONN.SW), Samsung Biologics (207940.KS).
Is Amgen expensive compared with its peers?
On forward p/e it trades at 18.3× against a peer median of 22.7×, 5th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has Amgen stock performed?
Over six months to 18 Nov 2026 the shares returned +33.9% against +29.1% for the median peer; over one year +32.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.